NEW YORK, January 23, 2019-- Attune Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of novel, orally-administered, small molecule therapeutics for the treatment of rare diseases, today announced the completion of a $23 million Series B financing. Venrock Healthcare Partners led the financing joined by new investor LifeSci Venture Partners, and existing investors RTW Investments, RA Capital, Boxer Capital and Tang Capital. In conjunction with the financing, Rod Wong, M.D., managing partner at RTW Investments, has been appointed to Attune’s board of directors.